IMUX

Immunic, Inc. Common Stock

$15.13 +1.14%

Recent alerts on IMUX

All signals →

News Immunic names Erik Lundgren as CEO; Daniel Vitt steps down

SEC filing IMUX Appoints Erik Lundgren as CEO, Advances Vidofludimus Calcium Through Late-Stage MS Trials

SEC filing IMUX Appoints Michael W. Bonney as Chair, Brings 30+ Years Biopharma Leadership Experience, MS Expertise

SEC filing IMUX Raises $200M in Private Placement, Reports Q1 2026 R&D Spend $25.6M

News Immunic GAAP EPS of -$1.08 misses by $0.12

SEC filing IMUX 1-for-10 Reverse Split Reduces Shares to 13.6M, Amends Charter, Meets Debt Covenants

SEC filing IMUX Retention Bonus $670K for CEO, $50B Deal, +94% YoY Growth

News Immunic garners new Buy at Guggenheim on lead asset

News Immunic rises after $400M private placement, leadership transition

SEC filing IMUX Announces $400M Private Placement, $200M Upfront, to Fund Phase 3 Trials, Commercialization

Short volume Short volume 64% of volume (5.7σ)

News MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

News MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

News MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

News MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

News Crown Brands Group Acquires Iconic Intimates Brand Hanky Panky

Get push alerts for IMUX

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS